Financial Data and Key Metrics Changes - Total revenues increased to $13 million in Q4 2025 from $11.9 million in Q4 2024, a 10% increase primarily driven by manufacture and supply revenue growth [18][19] - Full year 2025 total revenues decreased to $44.5 million from $57.6 million in 2024, a decline of 22.5% due to the one-time recognition of deferred revenues in the prior year [19][26] - R&D expenses decreased to $3.2 million in Q4 2025 from $4.9 million in Q4 2024, and for the full year, R&D expenses decreased to $17.2 million from $20.3 million [20][21] - Selling, general and administrative expenses increased to $32.8 million in Q4 2025 from $16 million in Q4 2024, primarily due to higher legal expenses and commercial spending [22][23] - Net loss for Q4 2025 was $31.9 million, compared to a net loss of $17.1 million in Q4 2024 [24][26] - Cash and cash equivalents as of December 31, 2025, were $121.2 million, with a guidance for 2026 total revenue of $46 million to $50 million [28][29] Business Line Data and Key Metrics Changes - Manufacture and supply revenue increased to $12 million in Q4 2025 from $10.7 million in Q4 2024, driven by increases in Suboxone and Ondif revenues [19] - Full year manufacture and supply revenue increased slightly to $40.2 million from $40 million in 2024, primarily due to increases in Ondif revenues [20] Market Data and Key Metrics Changes - The overall allergy market grew by just over 9% in Q4 2025, with EpiPen and generic auto injectors growing by approximately 5% [13] - Over 90% of prescriptions remain with auto-injectors, indicating a strong market preference for medical devices [14] Company Strategy and Development Direction - The company is focused on launching Anaphylm, with plans to file in Europe and Canada by the end of the year and to meet with the U.K. Health Authority [11] - The commercial strategy includes launching with 75 sales representatives, 50% more than previously planned, to enhance market penetration [12][42] - The company is also prioritizing out-licensing activities for Libervant and exploring partnerships for Anaphylm in international markets [15][90] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's future, citing a clear path for Anaphylm's market entry and a strong clinical team [8][10] - The management highlighted the importance of capital access for the drug launch and noted the extension of a revenue sharing agreement with RTW [13][18] - The company anticipates a non-GAAP adjusted EBITDA loss of $30 million to $35 million for 2026, reflecting ongoing costs associated with Anaphylm's NDA resubmission and pre-commercial activities [29][30] Other Important Information - The company reached a settlement in a long-standing defamation lawsuit, which is expected to reduce distractions from the business [14] - The FDA's recent denial of a competitor's citizen petition was seen as a validation of the company's data package [64] Q&A Session Summary Question: Confirmation of Type A meeting with the FDA - The company confirmed that a Type A meeting request has been submitted and is expected to occur within 30 days [32][33] Question: Goals for the FDA meeting - The goals include ensuring alignment on executing the requested studies and clarifying any minor protocol modifications [32][34] Question: RTW agreement extension - The extension until June 30, 2027, was made for flexibility, and the terms of the agreement remain unchanged [39][40] Question: Sales force expansion rationale - The decision to increase sales reps was driven by the need for deeper market penetration and greater efficiency in reaching key physicians [42][44] Question: Future clinical development of AQST-108 - The company indicated that AQST-108's development will be prioritized after Anaphylm's resubmission, but both projects are linked [86][87] Question: Promotional campaign adjustments - The company is refining its launch plan but does not anticipate fundamental changes in messaging or strategy [82][83] Question: Updates on the citizen petition and AAAAI conference takeaways - The FDA denied a competitor's petition, validating the company's data, and feedback from the AAAAI conference indicated strong interest in Anaphylm [64][66]

Financial Data and Key Metrics Changes - The company reported $6.7 million in neffy sales for Q4 2024 and $7.3 million for the full year 2024 since its launch in late September [42] - Total revenue for Q4 2024 was $86.6 million, including $73.5 million in collaboration revenue from ALK and $6 million from a licensing partner in Japan [49] - The company ended the year with $314 million in cash, cash equivalents, and short-term investments, providing a strong financial position for future growth [52][53] Business Line Data and Key Metrics Changes - Neffy generated $7.3 million in net product revenue in the U.S. since its launch, reflecting strong early adoption [15] - The company anticipates a significant inflection in prescribing depth and breadth as prior authorization headwinds diminish [15][17] Market Data and Key Metrics Changes - The U.S. epinephrine market represents a $3 billion annual net sales opportunity, with an additional $7 billion potential among untreated patients [9] - The company expects to achieve 80% unrestricted commercial coverage by early summer 2025, enhancing access for patients [19][20] Company Strategy and Development Direction - The primary focus for 2025 is accelerating neffy adoption and expanding global market access, with plans for a direct-to-consumer advertising campaign starting in May [21][54] - The company is also preparing for international commercialization, with regulatory submissions completed in multiple countries [22] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in neffy's potential to become a new standard of care in emergency allergy treatment, supported by positive feedback from healthcare providers [57] - The company is optimistic about achieving its payer coverage goals, which are expected to facilitate easier prescribing for physicians [17][19] Other Important Information - The company has made significant strides in payer coverage, with over 51% of commercially insured patients able to access neffy without prior authorization as of April 1 [8][64] - The neffy Experience Program has shown promising real-world data, indicating better outcomes compared to traditional epinephrine injections [12][29] Q&A Session Summary Question: What is the expected ramp for the 1 mg neffy product? - Management believes the 1 mg product will significantly impact sales, especially among children, as it represents 23% of the current auto-injector market [61] Question: Can you provide an update on the 80% access goal? - As of April 1, 51% of commercial patients have access without prior authorization, with expectations to reach 80% by July 1 [64][68] Question: What percentage of the epinephrine market is direct to patients? - Currently, most sales are retail, with little revenue from non-retail markets like airlines and schools, but growth is expected over time [73][74] Question: How long does prior authorization last for payers? - Prior authorization typically needs to be renewed for each prescription, creating a significant burden for physicians [90][92] Question: What would it mean if epinephrine went over the counter? - Management believes that while neffy is safe, the hurdles for over-the-counter status are significant, particularly regarding self-diagnosis and safety concerns [106][109] Question: What are the goals for the challenge clinic registry study? - The study aims to gather real-world safety data for neffy and will include an interim analysis to present preliminary findings [112][117]

Financial Data and Key Metrics Changes - The company reported $6,700,000 in Nephi sales for Q4 2024 and $7,300,000 for the full year 2024, reflecting strong early adoption since the product's launch in September 2024 [28][32] - Total revenue for Q4 2024 was $86,600,000, including collaboration revenue from ALK and other partners [31] - The company ended the year with $314,000,000 in cash and cash equivalents, providing a strong financial position for future investments [15][34] Business Line Data and Key Metrics Changes - Nephi generated $7,300,000 in net product revenue in the U.S. since its launch, indicating a strong initial commercial trajectory [10][28] - The company anticipates a significant increase in prescribing depth and breadth as prior authorization barriers diminish [10][11] Market Data and Key Metrics Changes - The U.S. epinephrine market represents a $3,000,000,000 annual net sales opportunity, with an additional $7,000,000,000 potential from untreated patients [6][10] - The company aims for over 80% unrestricted commercial coverage by early summer 2025, which is expected to enhance prescribing rates [12][14] Company Strategy and Development Direction - The primary focus is on accelerating Nephi adoption and expanding global market access, with plans for a direct-to-consumer advertising campaign starting in May 2025 [15][37] - The company is also working on advancing its intranasal epinephrine technology and plans to start Phase II studies in urticaria [39] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in Nephi's potential to become a new standard of care in emergency allergy treatment, supported by positive feedback from healthcare providers [39] - The company is optimistic about achieving its payer coverage goals and expects a significant inflection in prescribing as administrative barriers are reduced [11][14] Other Important Information - The company has made significant strides in payer coverage, with over 51% of commercially insured patients able to access Nephi without prior authorization as of April 1, 2025 [5][12] - The one milligram Nephi dose is expected to be available by May 2025, targeting a significant portion of the pediatric population [14][15] Q&A Session Summary Question: How is the ramp for the one milligram format expected to compare to the Tumig product? - Management believes the one milligram format will be additive and significantly impact sales, especially among children [42][44] Question: What is the progress toward the 80% access goal? - As of April 1, 2025, approximately 51% of commercial patients have access without prior authorization, with expectations to reach 80% by July 1, 2025 [45][49] Question: What percentage of the epinephrine market is direct to patients versus broader entities? - Currently, most sales are retail, with little revenue from non-retail markets like airlines and schools, but growth is expected over time [53][54] Question: How long does prior authorization last for payers that require it? - Prior authorization typically needs to be renewed for each prescription, creating a significant burden for physicians [61][62] Question: What is the upside expansion opportunity for previously untreated patients? - There is a significant opportunity to reengage previously untreated patients, with approximately 16.5 million diagnosed but untreated individuals [66][67] Question: What would it mean if epinephrine went over the counter? - While there is interest, significant hurdles exist regarding safety and self-diagnosis, making it unlikely in the near future [69][71] Question: What are the goals for the challenge clinic registry study for Nephi? - The study aims to gather real-world safety data and will likely present interim results at upcoming medical meetings [74][78]